Table of contents

Details Overview Explorer

Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams

FDA_FRDOC_0001-14290Notice

Comments

0

Awaiting comments

Deadline

--

Net supporti

—

Document

Details

The document's own metadata, straight from the source system.

Title: Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams

Posted: Jun 22, 2026
Comment period: Jun 22, 2026 – ?
Agency: Food and Drug Administration (FDA)
FR Doc: 2026-12367
Topics: Pharmaceutical Policy

View on regulations.gov ↗

Analysis

Overview

No comments yet.

Comments

Explorer

Every mirrored comment — filter by stance, campaign, or issue.

Filter:

No comments match.